Nitazoxanide against COVID-19 in three explorative scenarios
Authors:
- José Meneses CalderónJCJosé Meneses Calderón
- Leopoldo Paniagua CoriaLCLeopoldo Paniagua Coria
- Jesús Carlos Briones GarduñoJGJesús Carlos Briones Garduño
- Jazmín Meneses FigueroaJFJazmín Meneses Figueroa
- María José Vargas ContretasMCMaría José Vargas Contretas
- Srivatsan PadmanabhanSPSrivatsan Padmanabhan
- Hugo Mendieta ZerónHZHugo Mendieta Zerón
Open Access
- 30 September 2020
- journal article
- research article
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 14 (09) , 982-986
Abstract
Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.Keywords
This publication has 19 references indexed in Scilit:
- Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergencyScience of The Total Environment, 2020
- Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early managementPharmacological Research, 2020
- Drug repositioning is an alternative for the treatment of coronavirus COVID-19International Journal of Antimicrobial Agents, 2020
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitroAntiviral Research, 2020
- Delivery in pregnant women infected with SARS‐CoV‐2: A fast reviewInternational Journal of Gynecology & Obstetrics, 2020
- Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirusJournal of Infection and Public Health, 2016
- A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugsAntiviral Research, 2015
- Nitazoxanide: A first-in-class broad-spectrum antiviral agentAntiviral Research, 2014
- Treatment of intestinal parasitic infections: a review of nitazoxanideTrends in Parasitology, 2002